Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.

Original languageEnglish
Pages (from-to)167-180
Number of pages14
JournalSeminars in Ophthalmology
Volume26
Issue number3
DOIs
StatePublished - May 1 2011

Fingerprint

Macular Degeneration
Outcome Assessment (Health Care)
Clinical Trials
Genetic Predisposition to Disease
Pharmaceutical Preparations
Therapeutics
Neuroprotection

Keywords

  • age-related macular degeneration
  • clinical trials
  • drusen
  • geographic atrophy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{6d05efc396ad46e09749c57ff3e9d429,
title = "Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures",
abstract = "Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.",
keywords = "age-related macular degeneration, clinical trials, drusen, geographic atrophy",
author = "Zohar Yehoshua and Rosenfeld, {Philip J} and Albini, {Thomas A}",
year = "2011",
month = "5",
day = "1",
doi = "10.3109/08820538.2011.577132",
language = "English",
volume = "26",
pages = "167--180",
journal = "Seminars in Ophthalmology",
issn = "0882-0538",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures

AU - Yehoshua, Zohar

AU - Rosenfeld, Philip J

AU - Albini, Thomas A

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.

AB - Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.

KW - age-related macular degeneration

KW - clinical trials

KW - drusen

KW - geographic atrophy

UR - http://www.scopus.com/inward/record.url?scp=79957594942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957594942&partnerID=8YFLogxK

U2 - 10.3109/08820538.2011.577132

DO - 10.3109/08820538.2011.577132

M3 - Article

VL - 26

SP - 167

EP - 180

JO - Seminars in Ophthalmology

JF - Seminars in Ophthalmology

SN - 0882-0538

IS - 3

ER -